Definitions
Sorry, no definitions found. Check out and contribute to the discussion of this word!
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word bardoxolone.
Examples
-
Another promising pipeline candidate in the company's pipeline is bardoxolone, which is scheduled to enter into phase III studies in early 2011 for chronic kidney disease.
-
Abbott believes bardoxolone has blockbuster potential—meaning it could achieve annual sales exceeding $1 billion—and could reach the market by 2014.
Abbott Labs Licenses Molecules from Reata Jonathan D. Rockoff 2011
-
He said it would have nearly $18 billion in yearly sales and grow in the low-single digits the next few years before accelerating after the launch of some drugs in phase 3 development, such as bardoxolone for chronic kidney disease.
Abbott to Split Into Two Companies Jonathan D. Rockoff 2011
-
Last year , Abbott paid Reata $450 million for international rights—excluding Japan, China and certain other Asian markets—for Reata's drug bardoxolone methyl, an agent now in late stage or phase III human testing for chronic kidney disease.
Abbott Labs Licenses Molecules from Reata Jonathan D. Rockoff 2011
-
The new pact covers hundreds of Reata molecules that work the same way and attack the same targets as bardoxolone, a fact that the companies say reduces the risk of the transaction.
Abbott Labs Licenses Molecules from Reata Jonathan D. Rockoff 2011
-
Abbott Laboratories has agreed to pay at least $450 million for international rights to develop and commercialize Reata Pharmaceuticals 'experimental chronic kidney-disease drug bardoxolone.
-
If we look at the geographies that we have rights to with bardoxolone, you'll know that chronic kidney disease is a significant drain on all of the medical systems, and really a significant cost to all but worldwide healthcare systems.
Abbott Laboratories CEO Discusses Q4 2010 Earnings Call Transcript - Seeking Alpha 2011
-
Also during the first half, we'll have 52-weak results from our by bardoxolone on Phase IIb study.
Abbott Laboratories CEO Discusses Q4 2010 Earnings Call Transcript - Seeking Alpha 2011
-
Through our agreement with Reata Pharmaceuticals, we acquired international rights to bardoxolone excluding certain Asian markets.
Abbott Laboratories CEO Discusses Q4 2010 Earnings Call Transcript - Seeking Alpha 2011
-
And one of the products -- I was very impressed with our bardoxolone results.
Abbott Laboratories CEO Discusses Q4 2010 Earnings Call Transcript - Seeking Alpha 2011
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.